Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: Results of the United States compassionate use program in 365 patients

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 5, 2006, Pages 887-894

  Rossignol, J F ^a  

^a Romark Institute for Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITAZOXANIDE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CHILD; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; FATALITY; FECES ANALYSIS; FECES INCONTINENCE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SCLERA DISEASE; SELF REPORT; SIDE EFFECT; SYMPTOMATOLOGY; UNITED STATES; URINE COLOR; VOMITING;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIPARASITIC AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CRYPTOSPORIDIOSIS; DIARRHEA; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX DISTRIBUTION; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 33747365552     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03033.x     Document Type: Article

References (13)

1. Hunter PR, Nichols G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev 2002; 15: 145-54.
2. Chen X-M, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N Engl J Med 2002; 346: 1723-31.
3. MacKenzie WR, Hoxie NJ, Proctor ME, et al. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply. N Engl J Med 1994; 331: 161-7.
4. Morpeth SC, Thielman NM. Diarrhea in patients with AIDS. Curr Treat Options Gastroenterol 2006; 9: 23-37.
5. Theodos CM, Griffiths JK, D'Onfro J, Fairfield A, Tzipori, S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother 1998; 42: 1959-65.
6. Blagburn B, Drain K, Land T, et al. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a Neonatal Mouse Model. Antimicrob Agents Chemother 1998; 42: 2877-82.
7. Gargala G, Delauney A, Li XD, Brasseur P, Favennec L, Ballet JJ. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite infected HCT-8 enterocytic cells. J Antimicrob Chemother 2000; 46: 57-60.
8. Li X, Brasseur P, Agnamey P, et al. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia Parasitol 2003; 50: 19-22.
9. Baishanbo A, Gargala G, Duclos C, et al. Efficacy of nitazoxanide and paromomycin on biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J Antimicrob Chemother 2006; 57: 353-5.
10. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective, double-blind placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184: 103-6.
11. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 2006; 4: 320-4.
12. Amadi B, Miwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002; 360: 1375-80.
13. Rossignol JF, Hidalgo H, Feregrino M, et al. A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in AIDS patients. Trans R Soc Trop Med Hyg 1998; 92: 663-6.